Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
13 angezeigte Treffer · Seite 3, keine Gesamtzahl für „Perjeta“
Suchtreffer
Begriffe & Kennungen
Perjeta · 4.8 · Rash In the pivotal trial CLEOPATRA in metastatic breast cancer, rash occurred in 51.7% of Perjeta-treated pat
Eintrag öffnenPerjeta · 4.8 · Reporting of suspected adverse reactions
Eintrag öffnenPerjeta · 4.8 · Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows con
Eintrag öffnenPerjeta · 4.8 · Summary of the safety profile
Eintrag öffnenPerjeta · 4.8 · System organ class Very Common Common Uncommon Rare
Eintrag öffnenPerjeta · 4.8 · Table 2 Summary of ADRs in patients treated with Perjeta in clinical trials^, and in the Post- marketing setti
Eintrag öffnenPerjeta · 4.8 · Table 2 summarizes the ADRs from the Perjeta-treated groups of the following pivotal clinical trials: • CLEOPA
Eintrag öffnenPerjeta · 4.8 · Tabulated list of adverse reactions
Eintrag öffnenPerjeta · 4.8 · The ADRs are listed below by MedDRA system organ class (SOC) and categories of frequency: Very common (≥ 1/10)
Eintrag öffnenPerjeta · 4.8 · The incidence of the following all grade adverse events was at least 5% higher in patients ≥ 65 years of age,
Eintrag öffnenPerjeta · 4.8 · The most common ADRs (≥30%) from this pooled data were diarrhoea, alopecia, nausea, fatigue, neutropenia, and
Eintrag öffnenPerjeta · 4.8 · The safety of Perjeta has been evaluated in more than 6,000 patients in Phase I, II, and III trials in patient
Eintrag öffnenPerjeta · 4.8 · Within each frequency grouping and SOC, ADRs are presented in the order of decreasing seriousness.
Eintrag öffnen